Defining the Value of a Comparative Approach to Cancer Drug Development

Area of Science:

• Oncology
• Translational Medicine
• Drug Development

Background:

• Comparative oncology utilizes naturally occurring animal cancers to study human cancer biology and treatment responses.
• Its application in drug development is often debated due to perceived regulatory uncertainties and impact on clinical trials.

Purpose of the Study:

• To examine the value of comparative oncology in drug development.
• To identify specific drug development questions best addressed by this approach.
• To address perceived risks and provide a framework for integrating comparative oncology data.

Main Methods:

• Review of existing literature and case examples.
• Analysis of potential applications and limitations of comparative oncology in preclinical and clinical settings.
• Discussion of regulatory considerations for data generated from comparative oncology studies.

Main Results:

• Comparative oncology can answer specific drug development questions, especially regarding efficacy and toxicity.
• Data from comparative oncology studies can be valuable, particularly for identifying drug-associated adverse events.
• The approach is best viewed as supplementary to conventional preclinical and human clinical studies.

Conclusions:

• Comparative oncology is a valuable tool that can satisfy unmet needs in cancer drug development.
• Regulatory bodies should consider comparative oncology data as informative and supplementary.
• Integrating comparative oncology data can enhance the efficiency and success of cancer drug development pipelines.